Biology and therapy of mantle cell lymphoma

Current Opinion in Oncology

Volumn 17, Issue 5, 2005, Pages 425-431

  Williams, Michael E ^a,b   Densmore, John J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bortezomib; Cyclin D1; Mantle cell lymphoma; Rituximab; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BIOLOGICAL MARKER; BORTEZOMIB; CARMUSTINE; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DEPRESSION; DIARRHEA; DNA MICROARRAY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LUNG HEMORRHAGE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MYALGIA; MYELODYSPLASIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; PROGNOSIS; STEM CELL TRANSPLANTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 24144472585     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000174039.69656.2b     Document Type: Review

References (36)

1. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol 2002; 33:7-20.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: ARC Press; 2001.
3. Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004; 45:2007-2015.
4. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol 2004; 124:130-140. This is an excellent concise review of the genetic basis and molecular characteristics of MCL.
5. Bertoni F, Conconi A, Cogliatti SB, et al. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. Br J Haematol 2004; 124:289-298. This analysis of MCL showed 11q22-23 deletions in about half of the 42 cases. Two distinct regions of deletion were identified, one encompassing the ATM gene and the other a nearby segment not involving ATM and suggesting a pathogenetically relevant gene(s) at that locus.
6. Babbage G, Garand R, Robillard N, et al. Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events. Blood 2004; 103:2795-2798. This brief report describes a study that demonstrated MCL subsets with mutated or unmutated VH genes, with activation-induced cytidine deaminase expression in both groups.
7. de Leeuw RJ, Davies JJ, Rosenwald A, et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 2004; 13:1827-1837.
8. Jarosova M, Papajik T, Holzerova M, et al. High incidence of unbalanced chromosomal changes in mantle cell lymphoma detected by comparative genomic hybridization. Leuk Lymphoma 2004; 45:1835-1846.
9. Tagawa H, Karnan S, Suzuki R, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24:1348-1358.
10. Kohlhammer H, Schwaenen C, Wessendorf S, et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004; 104:795-801. This detailed analysis of 49 MCL cases identified frequent sites of chromosomal gain or loss in the majority of samples; 8p- and 13q14- were associated with poorer overall survival.
11. Shen Y, Iqbal J, Xiao L, et al. Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. BMC Immunol 2004; 5:20.
12. Ek S, Bjorck E, Porwit-MacDonald A, et al. Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica 2004; 89:686-695.
13. Ghobrial IM, McCormick DJ, Kaufmann SH, et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 2005; 105:3722-3730. This was the first proteomic analysis of MCL, identifying a signature of dysregulated proteins compared with normal tonsillar B-cells.
14. Densmore JJ, Williams ME. Mantle cell lymphoma. Curr Treat Options Oncol 2003; 4:281-287.
15. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
16. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23:1984-1992. This prospective phase III trial demonstrated improved overall responses, complete response rates, and durability of responses with R-CHOP compared with CHOP alone, but without apparent cure or increased survival.
17. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11(Suppl 1):117-121.
18. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23:705-711. This clinical trial confirmed modest activity of single-agent weekly × four doses rituximab in MCL, but without benefit for prolonged treatment using a schedule of one dose every 2 months × 4 doses.
19. Romaguera J, Fayad L, Rodriguez A, et al. Rituximab plus HyperCVAD alternating with rituximab plus high-dose methotrexate-cytarabine in untreated mantle cell lymphoma: prolonged follow-up confirms high rates of failure-free survival and overall survival. Blood 2005; 104:40a. ([abstract].) An update of the R-HyperCVAD/Mtx/AraC regimen extending previously reported high response rates with this regimen in newly diagnosed MCL.
20. Kahl BS, McGovern J, Blank J, et al. Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study. Blood 2005; 104: 390a. (([abstract].)) This is a preliminary report of responses and toxicity of a modified R-HyperCVAD regimen administered with scheduled ritiximab retreatment.
21. Jacobsen E, Freedman A. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004; 16:106-113. This is a recent review of dose-intensive therapy with stem cell rescue in MCL.
22. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma - results of a prospective randomized trial of the European MCL network. Blood 2004; 105:2677-2684. This is an important multicenter prospective randomized trial demonstrating improved outcome for ASCT compared with IFN maintenance therapy after CHOP-like induction chemotherapy.
23. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15:283-290. In this clinical trial of 20 MCL patients treated with CHOP followed by an 'in-vivo purge' with rituximab 5 days before stem cell collection, patients then proceeded to autologous transplantation with two 4-week courses of rituximab at weeks 8 and 24 after transplantation. Progression-free and overall survival rates seemed to be improved in comparison with matched historical control individuals.
24. Geisler C, Elonen E, Kolstad A, et al. Nordic mantle cell lymphoma project: prolonged follow-up of 86 patients treated with BEAM/BEAC + PBSCT confirms that addition of high-dose Ara-C and rituximab to CHOP induction + in-vivo purging with rituximab increases clinical and molecular response rates, PCR-neg. grafts, failure-free, relapse-free and overall survival. Blood 2005; 104:6a [abstract]. This preliminary report supports more durable responses and survival favoring the incorporation of high-dose cytosine arabinoside plus rituximab into the pre-autologous SCT regimen for MCL.
25. Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16:618-624. In this review of 97 MCL patients treated with autologous (80) or allogeneic (17) SCT at the University of Nebraska, relapse rates were lower in the latter group, although event-free and overall survival rates at 5 years were similar in the two groups.
26. Kasamon YL, Jones RJ, Diehl LF, et al. Outcomes of autologous and allogeneic BMT for mantle cell lymphoma. Blood 2005; 104:257a. [abstract].
27. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104:3535-3542. This is an important analysis of matched related and unrelated stem cell transplants after nonmyeloablative conditioning in 33 patients with relapsed and refractory MCL, demonstrating sustained responses in more than half of treated patients. A graft-versus-lymphoma effect is suggested as contributing to the observed benefit.
28. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064-3071. This phase III trial demonstrated a survival benefit for R-FCM compared with FCM, despite the lack of significantly prolonged progression-free survival after R-FCM.
29. Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15:511-516.
30. Koenigsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma: a multicenter phase I/II Trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004; 45:1821-1827.
31. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory b-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-675. This report together with [32] demonstrates impressive activity of bortezomib in relapsed and refractory MCL, establishing its utility in this setting and the potential for enhanced responses when it is combined with immunochemotherapy.
32. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and Mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684. See [31].
33. Fisher RI. Mantle cell lymphoma: at last: some hope for successful innovative treatment strategies. J Clin Oncol 2005; 23:657-658. This report provides a useful perspective on the place of, and potential for, bortezomib in MCL therapy, with a summary of current multicenter trials aimed at extending the work of [31,32].
34. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104:2269-2271. This interesting report shows an 81% overall response rate in a small series of patients with relapsed or refractory MCL, although the majority required thalidomide dose modifications because of toxicity.
35. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:1740-1745.
36. Witzig TE, Geyer S, Ghobrial IM, et al. Anti-tumor activity of single-agent CCI-779 for relapsed mantle cell lymphoma: a phase II trial in the North Central Cancer Treatment Group. Blood 2005; 104:40a. [abstract].